A lower dose (450 mg daily) of valganciclovir was equally effective in preventing CMV disease than a higher dose (900 mg daily), but adverse effects like needing G-CSF or dose reduction of valganciclovir due to leukopenia were more common in the group receiving higher dose (27). The gene discussed is CSF3; the disease is Decreased total leukocyte count.